Current filters:  
Canada
Healthcare
Canada
Blake, Cassels & Graydon LLP
Canada has a vibrant life sciences and pharmaceutical industry, with a broad array of firms conducting research and developing innovative medicines, generic medicines, biosimilar products...
Smart & Biggar
On June 4, 2020 the Federal Court dismissed an application for judicial review brought by Canada RNA Biochemical Inc of Health Canada's refusal of C-RNA's application for a natural health product...
Smart & Biggar
On June 3, 2020, a proposed class action was commenced against over 50 generic drug manufacturers.
Smart & Biggar
Further to our June 1, 2020 update, regulations amending the coming into force date of the Regulations Amending the Patented Medicines Regulations
MLT Aikins LLP
Changes are coming to the Canadian grain system as a result of the Canada-United States-Mexico Agreement ("CUSMA") which is set to come into effect on July 1, 2020. On June 23, 2020, the Canadian Grain Commission announced...
Fasken
Measures implemented over the past two weeks by governments across Canada to respond to the COVID-19 outbreak focus on safely re-opening various businesses and services, including...
Torys LLP
Over the last several years, there has been a great deal of uncertainty regarding Canada's patented drug pricing regime.
Smart & Biggar
Generally, the revised Guidelines add complexity to the price review process for new patented medicines.
Blake, Cassels & Graydon LLP
COVID-19 is transforming the way businesses create products and go-to-market, especially when launching health products during a pandemic, on an expediated timeline.
Smart & Biggar
The PMPRB has just released revised draft Guidelines operationalizing the amended Patented Medicines Regulations, simultaneously beginning a 30-day consultation period.
Norton Rose Fulbright Canada LLP
Amendments to the Patented Medicines Regulations are scheduled to come into force on January 1, 2021.
Norton Rose Fulbright Canada LLP
We previously reported on the Ontario government's efforts to manage the risk of drug shortages in the early days of the pandemic.
Torkin Manes LLP
Neil Abramson, of our Health Law Group, spoke at the OBA Health Law Section program on June 10th titled "Emerging From the Crisis: Understanding the Impact on Health Law".
Gowling WLG
On June 10, 2020, Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) ("Innocan") announced the closing of its marketed short form prospectus offering of units for gross proceeds of $5,116,309.74.
Norton Rose Fulbright Canada LLP
En cette période d'incertitude et compte tenu du contexte juridique et réglementaire qui évolue rapidement, le secteur agroalimentaire
Gowling WLG
Changes appear to be on the horizon for BC's health professional regulatory framework, and it could be significant.
Bennett Jones LLP
In connection with the COVID-19 pandemic and the many restrictions that have been placed on health related services, the CRA has recognized that members of a HCSA might not be able to use HCSA credits ...
Fasken
Measures implemented over the past two weeks by governments across Canada to respond to the COVID-19 outbreak focus on safely re-opening various businesses and services.
Smart & Biggar
Health Canada has recognized for many years that the current regulatory regime on drug sampling, which significantly restricts the distribution of drug samples to both consumers and health care...
Smart & Biggar
Webinar (June 16, 2020): Smart & Biggar's Alice Tseng and Mark Biernacki join forces with Ad Standards' Chief Legal & Policy Officer Catherine Bate to explore current issues in Advertising...
FREE News Alerts
Sign Up for our free News Alerts - All the latest articles on your chosen topics condensed into a free bi-weekly email.
Upcoming Events
Tools
Font Size:
Translation
Mondaq Social Media